ACUTE MYELOID LEUKEMIA
Showing 51 - 75 of >10,000
Acute Myeloid Leukemia Trial in Beijing (Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte
Recruiting
- Acute Myeloid Leukemia
- Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
- "3+7"
-
Beijing, Beijing, ChinaChinese PLA General Hospital
Sep 29, 2023
Myeloproliferative Tumor, Secondary Leukemia Trial (Multiomic characterization, In vitro drug screening)
Not yet recruiting
- Myeloproliferative Neoplasm
- Secondary Leukemia
- Multiomic characterization
- In vitro drug screening
- (no location specified)
Aug 28, 2023
Acute Myeloid Leukemia Trial in Beijing, Tianjin (LCAR-AMDR Cells Product)
Recruiting
- Acute Myeloid Leukemia
- LCAR-AMDR Cells Product
-
Beijing, Beijing, China
- +1 more
Jan 28, 2023
Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial (UAE Inhibitor TAK-243)
Not yet recruiting
- Myelodysplastic Syndrome
- +4 more
- UAE Inhibitor TAK-243
- (no location specified)
Oct 20, 2022
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous
Recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +6 more
- Decitabine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 31, 2022
Acute Myeloid Leukemia (AML) Trial in Austria, Italy, Spain (Ivosidenib Oral Tablet, Azacitidine)
Not yet recruiting
- Acute Myeloid Leukemia (AML)
- Ivosidenib Oral Tablet
- Azacitidine
-
Vienna, Austria
- +3 more
Jun 8, 2023
Acute Myeloid Leukemia Trial in Nanjing (Venclexta 100 MG Oral Tablet)
Recruiting
- Acute Myeloid Leukemia
- Venclexta 100 MG Oral Tablet
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Jun 11, 2023
Acute Myeloid Leukemia and Myelodysplastic Syndrome Trial in Tianjin (QLF32101)
Not yet recruiting
- Acute Myeloid Leukemia and Myelodysplastic Syndrome
-
Tianjin, Tianjin, ChinaInstitute of Hematology&Blood Diseases Hospital,Chinese Academy
Jan 27, 2023
Leukemia, Myeloid, Acute Trial in Guangzhou, Hangzhou (BG1805)
Not yet recruiting
- Leukemia, Myeloid, Acute
- BG1805
-
Guangzhou, Guangdong, China
- +2 more
Nov 1, 2023
Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia Trial in Boston (Cytokine-Induced Memory-like Natural Killer
Not yet recruiting
- Acute Myeloid Leukemia
- +3 more
- Cytokine-Induced Memory-like Natural Killer Cells
- +2 more
-
Boston, Massachusetts
- +1 more
Nov 22, 2023
Relapsed/Refractory Acute Myeloid Leukemia Trial in Hefei (gdT cell injection targeting B7-H3 chimeric antigen receptor)
Recruiting
- Relapsed/Refractory Acute Myeloid Leukemia
- gdT cell injection targeting B7-H3 chimeric antigen receptor
-
Hefei, Anhui, ChinaPersonGen Anke Cellular Therapeutice Co., Ltd.
Jan 31, 2023
Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in
Not yet recruiting
- Acute Myeloid Leukemia
- Genetic Predisposition to Disease
- Collection of blood sample of bone marrow (cohort 1)
- Collection of blood sample of bone marrow (cohort 2 and 3)
- (no location specified)
Mar 6, 2023
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia Recurrent Trial in Beijing (CD123-CAR-NK cells)
Recruiting
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia Recurrent
- CD123-CAR-NK cells
-
Beijing, Beijing, ChinaThe Fifth Medical Center of Chinese People's Liberation Army (PL
Oct 24, 2022
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b) Trial
Completed
- Adult Acute Megakaryoblastic Leukemia (M7)
- +13 more
- Sirolimus
- +2 more
-
Philadelphia, PennsylvaniaThomas Jefferson University
Feb 2, 2023
Relapsed/Refractory Acute Myeloid Leukemia Trial in Beijing
Recruiting
- Relapsed/Refractory Acute Myeloid Leukemia
- Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
- Best-Available Therapy(BAT) Regimen
-
Beijing, Beijing, ChinaChinese PLA General Hospital
Oct 10, 2023
AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)
Not yet recruiting
- AML, Adult
- Minimal Residual Disease
- CD33/CLL1 dual CAR-NK cell
- +5 more
-
Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Aug 4, 2023
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
Recruiting
- Acute Myeloid Leukemia
- +6 more
- Biospecimen Collection
- +2 more
-
Orange, California
- +9 more
Jan 27, 2023
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Baltimore, Buffalo (Gemtuzumab Ozogamicin,
Recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Gemtuzumab Ozogamicin
- +4 more
-
Baltimore, Maryland
- +1 more
Dec 13, 2022
Acute Myeloid Leukemia Trial in Suzhou (Venetoclax Oral Tablet, Daunorubicin)
Recruiting
- Acute Myeloid Leukemia
- Venetoclax Oral Tablet
- Daunorubicin
-
Suzhou, Jiangsu, China
- +1 more
Jul 3, 2023
Acute Myeloid Leukemia, MDS Trial in Rochester, Houston (CTX-712)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
-
Rochester, Minnesota
- +1 more
Feb 15, 2023
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Trial in China (BL-M11D1)
Not yet recruiting
- Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
-
Hefei, Anhui, China
- +7 more
Jun 27, 2023
Novel Digital Array PCR for Acute Myeloid Leukemia (AML)
Recruiting
- Leukemia, Myeloid, Acute
- Minimal Residual Disease
-
Chapel Hill, North CarolinaNorth Carolina Cancer Hospital (NCCH)
Feb 2, 2023
MDS, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic Trial in Newcastle (Subcutaneous azacitidine, Oral
Not yet recruiting
- Myelodysplastic Syndromes
- +3 more
- Subcutaneous azacitidine
- Oral decitabine/cedazuridine
-
Newcastle, New South Wales, AustraliaCalvary Mater Newcastle
May 29, 2023